logo

Beigene (BGNE)



Trade BGNE now with
  Date
  Headline
8/9/2022 6:05:19 AM BeiGene Says Phase 3 RATIONALE 301 Trial With Tislelizumab Meets Primary Endpoint
7/14/2022 6:24:50 AM Beigene Says FDA Defers Action On BLA For Tislelizumab
7/12/2022 7:01:50 AM Leap Therapeutics Begins New DKN-01 Clinical Trials In Gastric Cancer, Colorectal Cancer And Endometrial Cancer
6/21/2022 7:15:34 AM BeiGene: Center For Drug Evaluation Of China NMPA Accepts SBLA For Anti-PD-1 Inhibitor Tislelizumab
6/10/2022 7:14:28 AM BeiGene Presents Data From Hematology Portfolio At EHA 2022 Hybrid Congress
5/11/2022 11:57:56 AM BeiGene Stock Down 13%
4/15/2022 6:04:46 AM BeiGene Says China NMPA Approves Tislelizumab For Patients With Second-Line Esophageal Squamous Cell Carcinoma
4/11/2022 6:07:52 AM BeiGene Announces Results From Phase 3 ALPINE Trial
3/11/2022 7:05:01 AM BeiGene: China NMPA Approves Tislelizumab For Microsatellite Instability-High Or Mismatch Repair-Deficient Solid Tumors
2/17/2022 5:10:29 AM BeiGene Announces Approval For BRUKINSA By Swissmedic For Adult Patients With Waldenstrm's Macroglobulinemia